Philadelphia FIGHT (FIGHT) was founded as the Community-Based Research Initiative on AIDS. Clinicians at FIGHT continue to be involved in a number of studies. Below are a list of clinical research trials at FIGHT.
The following clinical trials are ongoing and currently enrolling patients:
Studies of the Immunopathogenesis of Chronic and Emerging Viral Infections
Description: An observational blood draw study sponsored by The Wistar Institute, this study aims to collect blood specimens along with chart abstraction data to further our understanding of HIV. Eligible participants may be living with HIV and on or off ART, or be HIV negative.
Study to Compare Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) in Subjects with Chronic HCV Infection
Trial Number: AT-01B-007
Description: A phase 3, randomized, controlled, open-label study to compare the efficacy and safety of Bemnifosbuvir-Ruzasvir fixed-dose combination (BEM/RZR FDC) versus Sofosbuvir-Velpatasvir fixed-dose combination (SOF/VEL FDC) in subjects with chronic hepatitis C virus (HCV) infection
Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV PrEP
Trial Number: MK 011-00
Description: Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
Trial Number: GS-US-712-7286
Description: A Phase 3, Single-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Once-Yearly Intramuscular Lenacapavir for HIV Pre-exposure Prophylaxis (PrEP) in People With an Indication for PrEP
The following clinical trials are ongoing but are NOT currently enrolling new patients:
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who are Successfully Treated With a Complicated Regimen
Trial Number: GS-US-621-6289
Description: An operationally seamless Phase 2/3 randomized, open-label, multicenter, active-controlled study to evaluate the safety and efficacy of bictregravir/lenacapavir versus stable baseline regimen in virologically suppressed people with HIV-1 on stable complex treatment regimens
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
Trial Number: GS-US-621-6290
Description: A phase 3 double-blind multicenter randomized active-controlled study to evaluate the safety and efficacy of bictegravir/lenacapavir versus Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in virologically suppressed people with HIV-1
Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir (LEN) for HIV Pre-Exposure Prophylaxis (PrEP)
Trial Number: GS-US-528-9023
Description: A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People ≥ 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection
Acceptability of Long-Acting Injectable Lenacapavir (LEN) Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for HIV Pre-Exposure Prophylaxis (PrEP): Qualitative Insights Into Social and Behavioral Contexts
Trial Number: GS-US-528-6364
Description: A Qualitative Study for participants already enrolled in GS-US-528-9023 to examine Acceptability of Long-Acting Injectable Lenacapavir Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Nonbinary People
For more information on any of the clinical trials listed, please contact the Research Department at 215-344-1631.